These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 21785824)
21. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Castellano G; Malaponte G; Mazzarino MC; Figini M; Marchese F; Gangemi P; Travali S; Stivala F; Canevari S; Libra M Clin Cancer Res; 2008 Nov; 14(22):7470-80. PubMed ID: 19010864 [TBL] [Abstract][Full Text] [Related]
22. Effects of the combination of hyperbaric oxygen and 5-fluorouracil on proliferation and metastasis of human nasopharyngeal carcinoma CNE-2Z cells. Peng ZR; Zhong WH; Liu J; Xiao PT Undersea Hyperb Med; 2010; 37(3):141-50. PubMed ID: 20568543 [TBL] [Abstract][Full Text] [Related]
23. Osteopontin expression in nasopharyngeal carcinoma: its relevance to the clinical stage of the disease. Wang HH; Wang XW; Tang CE J Cancer Res Ther; 2011; 7(2):138-42. PubMed ID: 21768699 [TBL] [Abstract][Full Text] [Related]
24. [Knocking down osteopontin expression by specific siRNA reduces the in vitro invasiveness of human hepatocellular carcinoma cells]. Zhu XQ; Ye QH; Lei KF; Chen J; Qin LX Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):404-7. PubMed ID: 17152482 [TBL] [Abstract][Full Text] [Related]
25. Osteopontin promotes the progression of gastric cancer through the NF-κB pathway regulated by the MAPK and PI3K. Liu J; Liu Q; Wan Y; Zhao Z; Yu H; Luo H; Tang Z Int J Oncol; 2014 Jul; 45(1):282-90. PubMed ID: 24756245 [TBL] [Abstract][Full Text] [Related]
26. Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression. Zhang Y; Forootan SS; Kamalian L; Bao ZZ; Malki MI; Foster CS; Ke Y Int J Oncol; 2011 Apr; 38(4):1083-91. PubMed ID: 21290088 [TBL] [Abstract][Full Text] [Related]
27. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Xia H; Ng SS; Jiang S; Cheung WK; Sze J; Bian XW; Kung HF; Lin MC Biochem Biophys Res Commun; 2010 Jan; 391(1):535-41. PubMed ID: 19931509 [TBL] [Abstract][Full Text] [Related]
28. Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor. Yang L; Zhao W; Zuo WS; Wei L; Song XR; Wang XW; Zheng G; Zheng MZ Chin Med J (Engl); 2012 Jan; 125(2):293-9. PubMed ID: 22340562 [TBL] [Abstract][Full Text] [Related]
29. Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells. Wu XL; Lin KJ; Bai AP; Wang WX; Meng XK; Su XL; Hou MX; Dong PD; Zhang JJ; Wang ZY; Shi L World J Gastroenterol; 2014 Aug; 20(30):10440-8. PubMed ID: 25132760 [TBL] [Abstract][Full Text] [Related]
30. Role of osteopontin in the regulation of human bladder cancer proliferation and migration in T24 cells. Xu ST; Guo C; Ding X; Fan WJ; Zhang FH; Xu WL; Ma YC Mol Med Rep; 2015 May; 11(5):3701-7. PubMed ID: 25591934 [TBL] [Abstract][Full Text] [Related]
31. Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP-2 and MMP-9. Sun W; Liu DB; Li WW; Zhang LL; Long GX; Wang JF; Mei Q; Hu GQ Int J Oncol; 2014 May; 44(5):1551-60. PubMed ID: 24603891 [TBL] [Abstract][Full Text] [Related]
32. Niflumic acid exhibits anti-tumor activity in nasopharyngeal carcinoma cells through affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Luo S; Huang G; Wang Z; Wan Z; Chen H; Liao D; Chen C; Li H; Li B; Chen L; Huang Z; He Z Int J Clin Exp Pathol; 2015; 8(9):9990-10001. PubMed ID: 26617707 [TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion. Philip S; Bulbule A; Kundu GC Glycoconj J; 2004; 21(8-9):429-41. PubMed ID: 15750784 [TBL] [Abstract][Full Text] [Related]
34. Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression. Malaponte G; Hafsi S; Polesel J; Castellano G; Spessotto P; Guarneri C; Canevari S; Signorelli SS; McCubrey JA; Libra M Biochim Biophys Acta; 2016 Mar; 1863(3):483-489. PubMed ID: 26381542 [TBL] [Abstract][Full Text] [Related]
35. Suramin inhibits the growth of nasopharyngeal carcinoma cells via the downregulation of osteopontin. Jiang S; Chen X; Li C; Zhang X; Zhang T; Yue Y; Yang G Mol Med Rep; 2012 Dec; 6(6):1351-4. PubMed ID: 22965338 [TBL] [Abstract][Full Text] [Related]
36. Identification of the amyloid β-protein precursor and cystatin C as novel epidermal growth factor receptor regulated secretory proteins in nasopharyngeal carcinoma by proteomics. Tang CE; Guan YJ; Yi B; Li XH; Liang K; Zou HY; Yi H; Li MY; Zhang PF; Li C; Peng F; Chen ZC; Yao KT; Xiao ZQ J Proteome Res; 2010 Dec; 9(12):6101-11. PubMed ID: 20882990 [TBL] [Abstract][Full Text] [Related]
37. Osteopontin--an important downstream effector of S100A4-mediated invasion and metastasis. Berge G; Pettersen S; Grotterød I; Bettum IJ; Boye K; Mælandsmo GM Int J Cancer; 2011 Aug; 129(4):780-90. PubMed ID: 20957651 [TBL] [Abstract][Full Text] [Related]
38. Regulation of osteopontin and related proteins in rat CC531 colorectal cancer cells. Georges R; Adwan H; Zhivkova M; Eyol E; Bergmann F; Berger MR Int J Oncol; 2010 Aug; 37(2):249-56. PubMed ID: 20596651 [TBL] [Abstract][Full Text] [Related]
39. Osteopontin promotes EZH2 expression and tumor progression in nasopharyngeal carcinoma. Ma R; Luo X; Feng S; Li J; Fan Y; Wen W; Li H ORL J Otorhinolaryngol Relat Spec; 2014; 76(5):273-81. PubMed ID: 25471249 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of osteopontin suppresses in vitro and in vivo angiogenesis in endometrial cancer. Du XL; Jiang T; Sheng XG; Gao R; Li QS Gynecol Oncol; 2009 Dec; 115(3):371-6. PubMed ID: 19783287 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]